π Ionis $IONS craters ~20% premarket β eplontersen heart trial misses endpoint
Ionis Pharmaceuticals and partner AstraZeneca disclosed their CARDIO-TTRansform Phase 3 trial of eplontersen in ATTR-CM heart patients failed to meet the primary endpoint of reducing cardiovascular mortality and recurrent CV events vs. placebo at Week 140. A subgroup of patients NOT on stabilizers showed a nominally significant 29% risk reduction, keeping some hope alive for label discussions. IONS is down ~19-20% as Wall Street reprices the revenue outlook. Not financial advice. Is this a flush-and-buy setup for IONS, or does the Phase 3 miss break the bull case entirely?